Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Definitions

• the invention relates to individually dosed administration forms for pharmaceutically active compounds, consisting of non-tabletted, chewable gel compositions packaged in blisters or cavities; to a process for the manufacture of such individually dosed administration forms; to individually dosed administration forms obtainable by the above-mentioned process; and to the use of a stabilising agent to enhance the ease of removal of the composition from the blisters or cavities.
• Chewable delivery systems such as chewing gums, are highly desirable means for the oral administration of pharmaceutically active compounds.
• a disadvantage of chewing gum compositions is that they generally include a water insoluble gum base, which remains in the mouth and must be disposed of.
• many active compounds may have affinity for the gum base, making thus accurate dosing difficult.
• British Patent application GB 2 009 597 discloses chewable and swallowable, gelled antacid compositions.
• the compositions are obtained by dispersing an antacid in a solution comprising water, a carbohydrate or a polyhydric alcohol as a bodying agent and an amount of gelling agent sufficient to cause the liquid dispersion to set to a self- supporting gel after cooling.
• the still liquid dispersion can be poured before cooling into oral unit dosage moulds and allowed to set.
• compositions comprise fats, fatty oils or fat derivatives to improve the light stability of the dyes used to colour the gelatine compositions.
• the specification states that all fats, fatty oils or fat derivatives of synthetic or natural origin, as well as partially hydrogenated products can be used, provided that they are physiologically safe.
• the inventors have solved this problem by inco orating into a matrix material, comprising a mixture comprising a gelatine at least one water-soluble alcohol and/or water as a solvent and at least one stabilising agent selected from the group consisting of esters of glycerine and fatty acids and products resulting from the alcoholysis / esterification reaction of such esters of glycerine and fatty acids with - poly ethylenegly cols, the stabilising agent having a melting point in the range of 42° C to 63° C.
• These administration forms can be removed from the packaging without leaving residues.
• only one stabilising agent is incorporated into the matrix material.
• the composition of the present invention comprises at least one pharmaceutically active substance, gelatine present in an amount of at least 0,2% by weight of the composition, at least one stabilising agent as described above, and at least one water-soluble alcohol and/or water as a solvent, wherein water is present in an amount not greater than 46% by weight of the composition. It may also comprise bodying agents that impart texture and body to the final gel, and other optional components such as preservatives, antioxidants, defoaming agents, sweeteners, taste- masking agents, colour and flavours. It is a preferred embodiment of the present invention that only one stabilising agent is used.
• the bodying agents suitable for the present invention are sugars such as glucose, sucrose and fructose, sugar alcohols such as sorbitol, mannitol and maltitol and polysaccharides such as starch, cellulose and functionalised cellulose derivatives.
• non-tabletted, individually dosed administration forms of the present invention have compositions showing no plastic deformation at temperatures below 37°C.
• Gelatine is a protein obtained by extraction from animal raw materials containing collagen such as skins and bones, which have been previously conditioned by acidic or alkaline treatment. Commercially available gelatine typically contains 84-92% protein, 0, 1 -2% salts and the rest is water.
• gelatines are classified according to the raw material from which they have been obtained and according to their ability to gel, which is customarily measured as Bloom gel strength.
• gelatine Although all types of gelatine can be used for the manufacture of the individually dosed adniinistration forms of the present invention, it has been found that gelatines with a Bloom range comprised between 140 and 270 degrees Bloom, preferably between 180 and 250 degrees Bloom yield composition with optimum consumer acceptance in terms of palatability. Gelatines obtained though alkaline treatment are in general preferred to those obtained through acidic treatment. It is preferred that the compositions of the present invention comprise gelatine in an amount greater than 0,2% by weight of the composition, more preferably greater than 1% by weight and still more preferably greater than 5% by weight of the composition.
• the stabilising agent of the present invention is selected from the group consisting of esters of glycerine and fatty acids and products resulting from the alcoholysis / esterification reaction of such esters of glycerine and fatty acids with poly ethylenegly cols having a melting point in the range of 42° C to 63° C.
• stabilising agents are the mono-, di- and triesters of glycerine with fatty acids and mixtures thereof, preferably the diesters of glycerine with fatty acids.
• Preferred fatty acids are those selected from C10-C20, preferably C16-C18, unsaturated, saturated fatty acids. Examples of such fatty acids are lauric, oleic, linoleic, linolenic, palmitic and stearic acids.
• An example of a preferred commercially available ester is Estol ® 3745 GDS T2 from Uniqema.
• Other examples of stabilising agents are the products of the alcoholysis/esterification reaction of the esters of glycerine and fatty acids mentioned above. Preferred examples are products of the alcoholysis/esterification reaction of hydrogenated palm kernel oil or hydrogenated palm oil with PEG 1500, such as Gelucire ® 44/14 and Gelucire ⁇ S> 50/13 from Gattefosse.
• the solvent or solvents present in the composition is/are used in a total amount greater than 10% by weight, more preferably greater than 25% by weight still more preferably greater than 50% by weight of the composition.
• the amount of water of the present compositions is not greater than 46% by weight, preferably not greater than 35% by weight, most preferably not greater than 25% by weight, most preferably not greater than 15% by weight of the composition.
• the compositions of the present invention comprise at least one pharmaceutically active substance which is dispersed or dissolved within the matrix material when it is in the molten state.
• the pharmaceutically active substance need not be in any specific form for its successful incorporation within the molten matrix material, in particular it is not required, and also not preferred, that the pharmaceutically active substance is provided as a component of a shearform matrix carrier prepared by flashflow processing.
• Suitable pharmaceutically active substances that may be contained in the individually dosed administration forms of the present invention vary widely and generally represent any stable drug combination. Illustrative categories and specific examples include:
• Inorganic or organic salts of aluminium for example, aluminium allantoinate, aluminium aminoacetate, aluminium phosphate, aluminium silicate, aluminium glucoheptanoate or aluminium polygalacturonate.
• Inorganic or organic salts of bismuth for example, bismuth aluminate, bismuth carbonate, bismuth silicate, bismuth subcarbonate or bismuth citrate.
• Inorganic or organic salts of calcium for example, calcium phosphate or calcium aminoacetate.
• Inorganic or organic salts of magnesium for example, magnesium carbonate, basic magnesium carbonate, magnesium phosphate or magnesium silicate.
• Oxides and hydroxides such as aluminium oxide, algeldrate (aluminium hydroxide), magnesium or calcium oxides or hydroxides.
• Oxides and hydroxides such as aluminium oxide, algeldrate (aluminium hydroxide), magnesium or calcium oxides or hydroxides.
• Oxides and hydroxides such as aluminium oxide, algeldrate (aluminium hydroxide), magnesium or calcium oxides or hydroxides.
• Sennatin Sennosides A + B, Glycerol, Picosulfate, Lactitol, Bisacodyl, Polyethylene glycol, Lactulose, Basic magnesium carbonate, and mixtures thereof.
• ANTIOBESITY PRODUCTS Orlistat, Amfebutamone, Bupropion, Diethylpropion, Sibutramine, Fluoxetine, Metaraminol, Mazindol, Chorionic gonadotrophin, Phenterrnihe, Metamfetamine, Phendimetrazine, Benzfetamine, Phenylpropanolamme, Fenproporex, and mixtures thereof.
• Amilase Cellulase, Lactase, Lipase, and mixtures thereof.
• Isosorbide mononitrate or dinitrate Nitroglycerol, Pentaery ⁇ hrityl tetranitrate, Molsidomine, and mixtures thereof.
• ANTIHYPERTENSINES ALPHA ADRE ⁇ ORECEPTOR ANTAGONISTS
• Doxazosin Urapidil, Nipradilol, Indoramin, Prazosin, Labetalol, Amosulalol, Terazosin, Monatepil, and mixtures thereof.
• Dihydroergocristine Piracetam, Nicergoline, Vmburnine, Cadralazine, Flunarizine, Metergoline, Hydralazine, Fasudil, Nicorandil, Lrnsidomine, Sildenafil, Cmnarizine, Heptaminol, Almitrine, Raubasine, Pentoxifyline, Trimetazidine, Buflomedil, Alprostadil, Brovincamine, Cinepazet, Dilazep, Lidoflazine, Molsidomine, Nicorandil, Nifedipine, Trapidil, Viskenit, and mixtures thereof.
• Atenolol Esmolol, Carteolol, Metoprolol, Bisoprolol, Carvedilol, Nebivolol, Propranolol, Tertatolol, Betaxolol, Cetamolol, Nipradilol,- Tilisolol, Mepindolol,
• Olmesartan and mixtures thereof .
• Atorvastatin Lovastatin, Eptastatin, Simvastatin, Fluvastatin, Dalvastatin, Itavastatin, Rosuvastatin, Pravastatin, Probucol, Polycosanol, Ciprofibrate, Fenofibrate, Benzafibrate, Clofibrate, Filicol, Gemfibrozil, Benfluorex, Colestyramine, Phytosterols, Acipimox, Binifibrate, Clinofibrate, Colestilan, Diethylaminoethyl Dextran, Colestrol, Etiroxate, Etofibrate, Gugulipid, Meglutol, Melinamide,
• ANTMEOPLASTIC AGENTS Ameticine, Atrimustine, Diaziquone, Spiromustine, Melphalan, Elmustine, Estramustine, Ranimustine, Dibromomulcitol, Tauromustine, Temozolomide, Carboplatin, Fotemustine, Aranose, Perfosfamide, Eptaplatin, Busulfan, Porfiromycin, Ifosfamide, Clorambucil, Altretamine, Cisplatin, Lomustine, Improsulfan, Mitobronitol, Mitolactol, Nedaplatin, Oxaliplatin, Prednimustine, Temozolomide, Treosuflan, Trofosfamide, Cyclophosphamide, Methotrexate, Butocin, Capecitabine, Carmofur, Cladiibine, Cytarabine, Doxifluridine, Enocitabine, Fludarabine, Gemcitabine, Pentostatin, Raltit
• ANTHNFLAMMATORY AND ANTIRHEUMATIC PRODUCTS Aceclofenac, Diclofenac, Ketorolac, Meloxicam, Naproxen, Piketoprofen, Acemetacin, Alclofenac, Amfenac, Ampiroxicam, Azapropazone, Bufexamac, 'Butibufen, Carprofen, Chondroitin, Cinmetacin, Clidanac, Dexketoprofen, Diphenpyramide, Droxicam, Emorfazone, Enfenamic Acid, Epirizole, Etersalate,
• BISPHOSPHONATES Risedronate, Tiludronate, Clodronate, Pamidronate, Etidronate, Alendronate, Zoledronate, Cimadronate, Neridronate, Olpadronate, Minodronate, Ibandronate, and mixtures thereof.
• Meprobamate Buspirone, Suriclone, Citalopram, Brotizolam, Adinazolam, Etizolam, Bretazenil, Medicar, Enciprazine, Loflazepate, Propranolol, Chlordiazepoxide, Hydroxyzine, Trifluoperazine, Oxazepam, Medazepam, Clonazepam, Oxprenolol, Bromazepam, Clobazam, ⁇ ordazepam, Ketazolam, Halazepam, Alprozolam, Fluphenazine, CUorimipramine, Venlafaxine, Ritanserin, Ipsapirone, Tandospirone, Buspirone, Pazinaclone, Flesinoxan, Fluoxetine, Selfotel, Zatosetron, Pagoclone, Carpipramine, Sunepixron, Sertraline, Paroxetine, Cyclobenzaprine, Cyam
• Tranylcypromine Trimipramine, Desipramine, Opipramol, Nortriptyline, Protriptyline, Doxepin, Lithium Carbonate, CMorimipramine, Dosulepin, Trazodone, Butriptyline, Niloxazine, Maprotiline, Amoxapine, Lofepramine, Bupropion, Ritanserin, Doconexent, Paroxetine, Ipsapirone, Fengabine, Tandospirone, Setiptiline, Amfebutamone, Lazabemide, Flesinoxan, Adrafinil, Ademetionine, Modafinil,
• Pseudoephedrine Fluticasone, Indanazoline, Tinazoline, Ipratropium, and mixtures thereof.
• Chlorhexidine CMoramine-T, Benzalkonium Chloride, and mixtures thereof.
• Sulfamethoxazole Centella, Calcium Folinate, Palmidrol, Thiomucase, Glucomannan, Leucocianidol, Bacterial Lysate, Spagul, and mixtures thereof.
• active substance which can be present in the compositions according to the invention is selected from the group consisting of non-lipophilic active substances.
• the preferred pharmaceutically active substances are antacid compounds.
• the preferred antacids for use in the invention are generally carbonate or hydiOxycarbonate salts of calcium, magnesium, aluminium, or bismuth and combinations thereof, and are generally very water insoluble.
• Other antacids such as sodium bicarbonate, calcium bicarbonate, and other carbonates, silicates, and phosphates are included in this invention.
• Preferred antacids are aluminium and magnesium antacids, such as, for example, aluminium hydroxide and magnesium hydroxide and also preferred are crystalline aluminium magnesium hydroxy carbonates or sulphates such as hydrotalcite, magaldrate and almagate. Almagate is particularly preferred. Mixtures of antacid compounds may be used if desired.
• antiacids are used as pharmaceutically active substances they are present in amounts ranging from 5 to 50% by weight of the composition, preferably, between 10 and 45% by weight of the composition, more preferably between 20 and 35% by weight of the composition.
• compositions of the present invention preferably comprise water, more preferably at least 1 % wt. water, and do not comprise edible gums.
• the present invention relates also to a process for producing non-tabletted, individually dosed administration forms comprising the steps of: (a) forming a composition comprising at least one pharmaceutically active substance dispersed or dissolved within a matrix material comprising a mixture of gelatine, at least one stabilising agent and at least one water-soluble alcohol and/or water as a solvent, which is plastic at elevated temperature, and keeping such composition above 37° C in a heating tank, (b) transferring the composition, when it is fluid into a heated dosing apparatus, (c) discharging the composition onto a shaped substrate, through a controlled mechanism so that a constant quantity of the fluid formulation material is thereby dosed onto the substrate, (d) cooling the composition, wherein the stabilising agent or agents present in the composition is/are selected from the group consisting of esters of glycerine and fatty acids and products resulting from the alcoholysis / esterif ⁇ cation reaction of such esters with polyethyleneglycols and has a melting point in the range of 42
• an adhesion-reducing separating agent is placed on the inner surface of a cavity or a blister prior to step (c) of the above-mentioned process.
• adhesion-reducing separating agents are lecithin, talc, starch, vaseline, and fats which are fluid at 25°C.
• the cavities or blister of the individually dosed administration forms are made of a material selected from PVC (polyvinyl chloride), PVDC (polyvinylidene chloride), PP (polypropylene), Aclar or laminates such as OPA-Aluminium-PVC (oriented polyamide-aluminium-polyvinyl chloride). PVC is particularly preferred. (in full)
• the present invention relates to the use of at least one stabilising agent selected from the group consisting of (i) esters of glycerine and fatty acids (ii) products resulting from the alcoholysis / esterification reaction of such esters with poly ethylenegly cols, and having a melting point in the range of 42° C to 63° C to facilitate the removal from the blisters or cavities where they have been packaged, of compositions comprising pharmaceutically active substances dispersed or dissolved within a matrix material comprising a mixture of gelatine and at least one water- soluble alcohol and/or water as a solvent, which composition is plastic at elevated temperature.
• at least one stabilising agent selected from the group consisting of (i) esters of glycerine and fatty acids (ii) products resulting from the alcoholysis / esterification reaction of such esters with poly ethylenegly cols, and having a melting point in the range of 42° C to 63° C to facilitate the removal from the blisters or cavities where they have been packaged,
• plastic at elevated temperature is meant to designate a composition which can be molded at temperatures comprised between 45°C and 120°C and keeps its molded shape after it cools to 20°C.
• melting point is meant to designate the temperature at which the very last visible particle of a small substance's column introduced in a capillary melts as described in the European Pharmacopea 2.2.14.
• a suitable apparatus for this determination is the Melting Point Apparatus B-540 available from B ⁇ chi Labortechnik AG.
• non-tabletted administration form is intended to mean any form which has not been manufactured by using conventional tabletting processes such as the tabletting of granular or powdery compositions in an excentric or rotary press machine.
• ible gum is intended to mean polys accharide gums comprising among others gum arabic, gum tragacanth, agar agar, xanthan gum, alginates.
• water-soluble alcohol is meant to designate a pharmaceutically acceptable, liquid monohydric or polyhydric alcohol which can be mixed with water to form a uniform solution in a quantity of at least 10 volumes of alcohol per 100 volumes of water.
• examples of such alcohols are ethanol, n-propanol, iso-propanol, glycerol, propylene glycol, 1,3-butylene glycol and polyethylene glycols having a molecular weight comprised between 100 and 600 Dalton.
• compositions to be tested are manufactured according to the process described in example 1 and dosed into cylindrical cavities of circular cross-section having a diameter of 25 mm of a blister packaging made of PVC.
• the blister is thermo-sealed with an aluminium foil.
• the blisters are then stored in a climatic chamber at 40°C and 75% relative humidity for 10 weeks. After this period they are left at 25°C and 60% relative humidity for 24 hours.
• a panel consisting of 5 expert panellists is given 5 samples of the formulation each, and the panellists are asked to remove the composition from the blister where it is packaged by pressing with the thumb on the plastic wall of the cavity until the composition is expelled from the cavity through the aluminium foil. After the composition has been expelled the remaining aluminium sealing film is removed and the plastic cavity is visually inspected. The panellist are asked to give a sample the rating "Failed” if residues exceeding 0,5 mm in any dimension can be seen in the empty cavity. Otherwise the rating "Passed" must be assigned.
• composition of each individual cavity is as follows:
• compositions 2 to 7 were manufactured following the process described in example 1 modified in that 1900,8 gr of the glycerine solution were used, and in that 160 g. of a stabilising agent were added after the complete solubilisation of gelatine had taken place and before the addition of lecithin. After the solubilisation of gelatine the mixture was stirred for 20 minutes and the temperature of the reactor was raised to 75-80°C and 160 g of the stabilising agent were slowly and continuously added during approximately 5 minutes.
• compositions were manufactured following this process:
• compositions of examples 1 to 7 were subjected to the "removal from blister test" described above with the following results:

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Zoology (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Inorganic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=34610359

Family Applications (2)

Family Applications After (1)

Country Status (25)

Cited By (12)

Families Citing this family (7)

Citations (3)

Family Cites Families (10)

• 2003
  • 2003-11-10 ES ES200302612A patent/ES2235626B1/es not_active Expired - Fee Related
• 2004
  • 2004-03-11 WO PCT/EP2004/002513 patent/WO2005048975A1/en not_active Ceased
  • 2004-10-28 UY UY28586A patent/UY28586A1/es not_active Application Discontinuation
  • 2004-11-05 PE PE2004001080A patent/PE20050488A1/es not_active Application Discontinuation
  • 2004-11-08 AR ARP040104105A patent/AR048050A1/es not_active Application Discontinuation
  • 2004-11-08 MY MYPI20044643A patent/MY143793A/en unknown
  • 2004-11-09 JP JP2006538767A patent/JP4879021B2/ja not_active Expired - Fee Related
  • 2004-11-09 BR BRPI0416215-3A patent/BRPI0416215A/pt not_active IP Right Cessation
  • 2004-11-09 WO PCT/EP2004/012658 patent/WO2005048974A2/en not_active Ceased
  • 2004-11-09 AU AU2004290517A patent/AU2004290517B2/en not_active Ceased
  • 2004-11-09 DE DE602004030706T patent/DE602004030706D1/de not_active Expired - Lifetime
  • 2004-11-09 UA UAA200606335A patent/UA90253C2/ru unknown
  • 2004-11-09 RU RU2006120087/15A patent/RU2369379C2/ru not_active IP Right Cessation
  • 2004-11-09 NZ NZ546375A patent/NZ546375A/en unknown
  • 2004-11-09 ES ES04797734T patent/ES2358332T3/es not_active Expired - Lifetime
  • 2004-11-09 CN CNA2004800330379A patent/CN1878542A/zh active Pending
  • 2004-11-09 KR KR1020067009596A patent/KR20060116821A/ko not_active Ceased
  • 2004-11-09 AT AT04797734T patent/ATE492270T1/de not_active IP Right Cessation
  • 2004-11-09 CA CA002548615A patent/CA2548615A1/en not_active Abandoned
  • 2004-11-09 US US10/578,515 patent/US20070134318A1/en not_active Abandoned
  • 2004-11-09 EP EP04797734A patent/EP1682097B1/en not_active Expired - Lifetime
  • 2004-11-10 TW TW093134361A patent/TW200526266A/zh unknown
• 2006
  • 2006-03-24 ZA ZA200602416A patent/ZA200602416B/xx unknown
  • 2006-04-27 IL IL175285A patent/IL175285A/en not_active IP Right Cessation
  • 2006-05-08 EC EC2006006553A patent/ECSP066553A/es unknown
  • 2006-05-09 CO CO06043842A patent/CO5690531A2/es not_active Application Discontinuation
  • 2006-06-12 NO NO20062723A patent/NO20062723L/no not_active Application Discontinuation

Patent Citations (3)

Also Published As

Similar Documents

Legal Events